12:00 AM
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Bapineuzumab: Additional Phase III data

Additional data from the double-blind, North American Phase III Study 302 trial in 1,121 patients with mild to moderate AD who are carriers of the apolipoprotein E epsilon 4 (APOE4) genotype showed that in a subgroup of patients who received [11C] PiB PET scans (n=115), 0.5 mg/kg IV bapineuzumab significantly reduced amyloid burden from baseline to week 71 as measured by global cortical average standardized uptake value ratios (SUVR) vs. placebo (treatment difference of -0.101, p=0.004). In a subgroup of patients who underwent cerebrospinal...

Read the full 406 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >